Equillium to Present at Two Upcoming Investor Conferences

Rhea-AI Summary

Equillium (Nasdaq: EQ) is set to participate in the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 12:20 PM PT and the Jefferies Virtual London Healthcare Conference on November 18, 2021, at 12:00 AM PT. The presentations will cover the mechanism of action of itolizumab, aimed at treating severe autoimmune disorders. Leadership will conduct one-on-one meetings at both conferences. Webcast access is available on the company’s website, along with archive replays for 90 days.

LA JOLLA, Calif.--(BUSINESS WIRE)-- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will participate in fireside chat presentations at the Stifel 2021 Virtual Healthcare Conference and the Jefferies Virtual London Healthcare Conference.

Management will provide a high-level overview of itolizumab’s mechanism of action and review each of Equillium’s ongoing clinical programs, as well as data recently presented at ACR, ASN & ACAAI. Members of Equillium’s leadership team will be available for one-on-one meetings during both conferences.

Conference:		Stifel 2021 Virtual Healthcare Conference
Location:		Live Virtual Webcast on corporate website
Date:		Tuesday, November 16, 2021
Time:		12:20 PM Pacific Time | 3:20 PM Pacific Time

Conference:		Jefferies Virtual London Healthcare Conference
Location:		Recorded Virtual Webcast on corporate website
Date:		Thursday, November 18, 2021
Time:		12:00 AM Pacific Time | 3:00 AM Eastern Time

Webcast access for both presentations will be available on the “Events & Presentations” section of the Company’s website at https://ir.equilliumbio.com/events-and-presentations. An archived replay of both conferences will be available for 90 days.

About Equillium

Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD), lupus/lupus nephritis and uncontrolled asthma.

For more information, visit www.equilliumbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005733/en/

Investor Contact

Michael Moore

Vice President, Investor Relations & Corporate Communications

619-302-4431

ir@equilliumbio.com

Media Contacts

Aljanae Reynolds

Wheelhouse Life Science Advisors

areynolds@wheelhouselsa.com

Source: Equillium, Inc.

FAQ

What is Equillium participating in on November 16, 2021?

Equillium will participate in the Stifel 2021 Virtual Healthcare Conference on November 16, 2021.

What will Equillium present at the Jefferies Virtual London Healthcare Conference?

Equillium will present on itolizumab’s mechanism of action and discuss ongoing clinical programs at the Jefferies Virtual London Healthcare Conference.

What time is Equillium's presentation at the Stifel Conference?

Equillium's presentation at the Stifel Conference is scheduled for 12:20 PM Pacific Time.

Where can I access the webcasts for Equillium's presentations?

Webcasts for Equillium's presentations will be available on the 'Events & Presentations' section of their corporate website.

What is itolizumab being developed for by Equillium?

Itolizumab is being developed by Equillium to treat severe autoimmune and inflammatory disorders.